Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MGTX with free AI briefings, catalyst countdowns, and dilution alerts.

MGTX · MeiraGTx Holdings plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$143.2M Cash on Hand
41.4mo Cash Runway
Follow MGTX by email Get an email when MGTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MGTX, unsubscribe in one click. Privacy

📣 What MGTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Botaretigene Sparoparvovec X-Linked Retinitis Pigmentosa Phase 3 · NCT04794101 Active not recruiting
Genetic: AAV5-hRKp.RPGR X-Linked Retinitis Pigmentosa Phase 3 · NCT04671433 Completed
AAV - CNGB3 Achromatopsia Phase 1/2 · NCT03001310 Completed
adeno-associated virus vector AAV- CNGA3 Achromatopsia Phase 1/2 · NCT03758404 Completed
AAV RPE65 Leber Congenital Amaurosis Phase 1/2 · NCT02781480 Completed
AAV2hAQP1: 1 x 10^12 vg/gland (both glands) Radiation-Induced Parotid Gland Hypofunction Phase 1 · NCT04043104 Completed
AAV2hAQP1: 3 x 10^10 vg/gland (both glands) Radiation-Induced Parotid Gland Hypofunction Phase 1 · NCT04043104 Completed
AAV2hAQP1: 3 x 10^11 vg/gland (both glands) Radiation-Induced Parotid Gland Hypofunction Phase 1 · NCT04043104 Completed
AAV2hAQP1: 3 x 10^12 vg/gland (single gland) Radiation-Induced Parotid Gland Hypofunction Phase 1 · NCT04043104 Completed
AAV2hAQP1: 1 x 10^11 vg/gland (both glands) Radiation-Induced Parotid Gland Hypofunction Phase 1 · NCT04043104 Completed
Cetoquagene Parvec Squamous Cell Head and Neck Cancer Phase 1 · NCT02446249 Completed
Prior exposure to AAV-CNGA3 or AAV-CNGB3 Achromatopsia N/A · NCT03278873 Terminated
AAV OPTIRPE65 Leber Congenital Amaurosis (LCA) N/A · NCT02946879 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MGTX holds $143.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.4M/quarter from operations, an estimated runway of 41.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGTX files for a raise →

👥 Who Owns MGTX

Insiders 15.4% Institutions (242 holders) 73.2% Public and other holders 11.4%
HolderTypeShares% of sharesAs of
PERCEPTIVE ADVISORS LLC
Director, 10% owner · +360,000 options
Insider 11,742,117 12.01% 2026-04-17
Rubric Capital Management LP Institution (13G, 5%+) 8,427,279 8.62% 2026-09-30
Alexandria Forbes
PRESIDENT & CEO, Director · +980,000 options
Insider 1,325,695 1.36% 2026-08-18
Richard Giroux
CFO & COO · +980,000 options
Insider 942,682 0.96% 2026-10-20
Stuart Naylor
CHIEF SCI OFCR, OPHTHALMOLOGY · +70,000 options
Insider 613,187 0.63% 2026-10-06
Keith R. Harris
Director · +106,441 options
Insider 200,000 0.20% 2026-06-10
Robert K Zeldin
CHIEF MEDICAL OFFICER · +100,000 options
Insider 172,888 0.18% 2026-02-21
Robert J Wollin
GENERAL COUNSEL AND SECRETARY · +100,000 options
Insider 57,377 0.06% 2026-02-21
Alan Sebulsky
Director · +100,000 options
Insider 34,500 0.04% 2026-09-23

Share count 97,730,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MGTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.